MSLN and ovarian cancer: However, we strongly believe that this model of drug delivery can also be applied to ovarian cancer due to our prior success in developing soluble, mesothelin-TR3 fusion proteins (MesoTR3 and Meso64TR3), which bind with high affinity to MUC16, highly expressed on ovarian cancer cells.